Sanofi transferred 20 drugs to Cheplapharm, received a 26.4% stake and paid Regeneron $1 billion
Sanofi handed Cheplapharm 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites, in exchange for a 26.4% stake in Cheplapharm; at the same time the company made a one‑time $1 billion payment to Regeneron to expand their global alliance with new immunology antibodies.
Key points
- Sanofi and Cheplapharm announced a strategic partnership under which Cheplapharm will take over 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites in Hungary, Singapore and France, while preserving existing labor agreements and ensuring uninterrupted supply.
- Sanofi will receive a 26.4% stake in Cheplapharm.
What happened
Sanofi and Cheplapharm announced a strategic partnership under which Cheplapharm will take over 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites in Hungary, Singapore and France, while preserving existing labor agreements and ensuring uninterrupted supply.
Through the deal, Sanofi will receive a 26.4% stake in Cheplapharm.
At the same time Sanofi expanded its alliance with Regeneron, paying a $1 billion upfront and agreeing to split 50% of development and commercialization costs for four new antibodies, with Regeneron handling research and Sanofi leading global commercialization.
Deal terms
Sanofi will receive a 26.4% stake in Cheplapharm.
The Regeneron deal includes a one‑time $1 billion payment and an equal split of future costs and profits (50% each).
Key considerations
Changes in revenue from mature products, the valuation of the Cheplapharm stake and the payment schedule with Regeneron could affect Sanofi’s financial results.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Sanofi
A notification in your browser or on your phone when we publish about Sanofi. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
